Home › Calculator › GILD Dividend Calculator 2026
GILD Dividend DRIP Calculator 2026
2.25% YieldHealthcareGilead Sciences, Inc. · NASDAQ
Price: $144.23 · Annual div: $3.25/share · Frequency: quarterly · Payout ratio: 48% · Ex-div: 2026-09-15
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When GILD pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your GILD snowball 📈
$10,000 in GILD → $18.3K in 10 years · $30.56/month
About Gilead Sciences, Inc. (GILD) — Dividend Analysis 2026
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Compare GILD with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full GILD DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open GILD position with:
🌍 GILD Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold GILD.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 2.25% | -0.55% | $225 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 1.91% | -0.89% | $191 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 1.80% | -1.00% | $180 / yr |
| 🇬🇧 UK ISA | 0% | 2.25% | -0.55% | $225 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.05% | -0.75% | $205 / yr |
| 🇨🇦 TFSA | 0% | 2.25% | -0.55% | $225 / yr |
| 🇨🇦 CA Taxable | 25% | 1.69% | -1.11% | $169 / yr |
| 🇦🇺 Super (pension) | 15% | 1.91% | -0.89% | $191 / yr |
| 🇦🇺 AU Taxable | 30% | 1.57% | -1.22% | $158 / yr |
| 🇩🇪 DE Taxable | 26.375% | 1.66% | -1.14% | $166 / yr |
| 🇫🇷 FR Taxable | 30% | 1.57% | -1.22% | $158 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 GILD Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $3.25/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 GILD Dividend Payment Schedule
GILD pays quarterly — 4 times per year. Ex-div: 2026-09-15.
📊 GILD vs Healthcare Benchmarks
How GILD compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for GILD sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ GILD Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Sale | 2026-10-01 | 12,000 | $147.72 | $1.77M | ||
| Sale | 2026-10-01 | 3,000 | $148.63 | $445.9K | ||
| M-Exempt | 2026-09-22 | 2,223 | — | — | ||
| M-Exempt | 2026-09-22 | 2,223 | — | — | ||
| F-InKind | 2026-09-22 | 768 | $152.67 | $117.3K | ||
| Sale | 2026-09-15 | 3,000 | $145.29 | $435.9K | ||
| Sale | 2026-09-15 | 1,600 | $143.69 | $229.9K | ||
| Sale | 2026-09-15 | 800 | $144.46 | $115.6K | ||
| Sale | 2026-09-15 | 600 | $145.29 | $87.2K | ||
| M-Exempt | 2026-09-10 | 2,797 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare GILD with peers: GILD vs AMGN · GILD vs BMY · GILD vs BSX
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where GILD earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the GILD dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Gilead Sciences, Inc. (GILD) is currently trading at $144.23, 8% below its 52-week high. The current dividend yield is 2.25% based on an annual payout of $3.25 per share.
Gilead Sciences offers a stable healthcare dividend supported by reasonable payout metrics.
AI SummaryGilead Sciences, Inc. presents a compelling profile for income-focused investors within the healthcare sector, trading at $144.23 with a market capitalization of $178.8B. The company offers an annual dividend of $3.25, translating to a yield of 2.25%. With a conservative payout ratio of 48% and a moderate P/E ratio of 21.3, the current distribution appears well-covered by earnings and financially sustainable over the near term. However, dividend growth has been relatively sluggish, reflected in a modest five-year dividend CAGR of 3.2%. While the strong coverage ratio ensures safety for existing payouts, future income expansion will likely remain subdued unless the company accelerates top-line revenue growth beyond its historical trajectory.
- Slower dividend growth trajectory with a 3.2% five-year CAGR
- Patent expirations and competitive pressures in core therapeutic markets
Generated by AI using live market data. For educational purposes only — not financial advice.
Latest GILD News
LiveHow investors use the GILD dividend calculator
Illustrative examples of common use cases, written by the DividendFlow team — not customer reviews.